Paper - WANFANG MED ONLINE

You Position: Home > Paper

Impact of coagulation function and anticoagulation therapy on liver fibrosis

( views:73, downloads:0 )

Author:: No author available

Journal Title:: World Chinese Journal of Digestology

Issue:: 10

DOI:: 10.11569/wcjd.v25.i10.897

Key Word:: 肝纤维化;凝血功能;抗凝治疗;高凝状态;Liver fibrosis;Coagulation function;Anticoagulation therapy;High coagulation state

Abstract： Liver cirrhosis and its complications,including esophageal and gastric variceal bleeding,hepatic encephalopathy,and ascites,can cause serious harm to human health.Therefore,treatment of liver fibrosis is key to the prevention and treatment of liver cirrhosis.In order to treat liver fibrosis to reduce humansuffering,medical experts and scholars have performed many clinical and animal studies to find safe,efficient and reliable drugs to slow the progression of hepatic fibrosis and even reverse the liver function.This review introduces the definition of liver fibrosis in China and other countries,discusses the effect of coagulation on the process of liver fibrosis and various anticoagulation therapies for liver fibrosis,and summarizes the advantages,disadvantages,and side effects of different anticoagulants in the prevention and treatment of liver fibrosis.

Reference

[1]潘福敏,黄文强,邓祖秋.丹参滴丸联合苦参素治疗大鼠肝纤维化的实验研究[J].2016,(1).
[2]朱云清,杨俊生,宗伟,等.丹参多酚酸盐注射液治疗乙肝肝纤维化61例[J].2012,(5).
[3]侯淑娅,包小洁,黄劲松,等.低相对分子质量肝素抗肝纤维化作用及对肝细胞生长因子表达的影响[J].2008,(1).
[4]姚立,余静,李珏.丹参软肝饮对肝纤维化大鼠肝功能及肾素-血管紧张素-醛固酮系统的影响[J].2011,(4).
[5]赵敦美.苦参素、复方丹参治疗慢性乙型肝炎肝纤维化效果观察[J].2005,(5).
[6]Jun Shi,Jing-Hua Hao,Wan-Hua Ren,etc.Effects of heparin on liver fibrosis in patients with chronic hepatitis B[J].2003,(7).
[7]杜建华.丹参联合恩替卡韦治疗慢性乙型肝炎的疗效观察[J].2014,(26).
[8]黄艳,黄成,李俊.肝纤维化病程中Kupffer细胞分泌的细胞因子对肝星状细胞活化增殖、凋亡的调控[J].2010,(1).
[9]Smith,C.B.,Hurdle,A.C.,Kemp,L.O.,etc.Evaluation of venous thromboembolism prophylaxis in patients with chronic liver disease[J].2013,8(10).
[10]Varalakshmi P,Deepa PR.Protective effects of certoparin sodium, a low molecular weight heparin derivative, in experimental atherosclerosis.[J].2004,339(1).
[11]Fontcuberta Boj J.New frontiers with bemiparin: use in special populations.[J].2010,70(Suppl.2).
[12]Armando Tripodi,Veena Chantarangkul,Massimo Primignani,etc.The international normalized ratio calibrated for cirrhosis (INRliver) normalizes prothrombin time results for model for end-stage liver disease calculation[J].2007,46(2).
[13]Intagliata, N. M.,Henry, Z. H.,Maitland, H.,etc.Direct Oral Anticoagulants in Cirrhosis Patients Pose Similar Risks of Bleeding When Compared to Traditional Anticoagulation[J].2016,61(6).
[14]Russmann,S.,Niedrig,D.F.,Budmiger,M.,etc.Rivaroxaban postmarketing risk of liver injury[J].2014,61(2).
[15]Tripodi,A.,Baglin,T.,Robert,A.,etc.Reporting prothrombin time results as international normalized ratios for patients with chronic liver disease[J].2010,8(6).
[16]Kamath, Patrick S.,Nichols, William L.,Chen, Dong,etc.From Vitamin K Antagonists to Liver International Normalized Ratio: A Historical Journey and Critical Perspective[J].2014,40(8).
[17]陈强谱.肝硬化门静脉高压症病人血液流变学研究[J].1994,(3).
[18]Wichert M,Kroger K,Gerken G,etc.Low-molecular-weight heparin in patients with advanced cirrhosis.[J].2011,31(1).
[19]Ananthakrishnan AN,McGinley EL,Ali M,etc.Deep vein thrombosis and pulmonary embolism in hospitalized patients with cirrhosis: a nationwide analysis.[J].2011,56(7).
[20]Patel MR,Mahaffey KW,Garg J,etc.Rivaroxaban versus warfarin in nonvalvular atrial fibrillation.[J].2011,365(10).
[21]Koyama, Yukinori,Xu, Jun,Liu, Xiao,etc.New Developments on the Treatment of Liver Fibrosis[J].2016,34(5).
[22]Russo,M.W.,Gulati,S.,Eskind,L.,etc.Coronary artery stents and antiplatelet therapy in patients with cirrhosis[J].2012,46(4).
[23]Nguyen GC,Wu H.Liver cirrhosis is associated with venous thromboembolism among hospitalized patients in a nationwide US study.[J].2010,8(9).
[24]Northup,P.G.,Caldwell,S.H..Coagulation in Liver Disease: A Guide for the Clinician[J].2013,11(9).
[25]戚忠金,阎小燕.活血化瘀法改善肝脏微循环障碍的实验研究[J].1998,(0S1).
[26]石艳芬,卢燕许,祝玉清.血府逐瘀汤联合恩替卡韦治疗慢性乙型肝炎肝纤维化临床观察[J].2013,(6).
[27].Role of anticoagulant therapy in liver disease[J].2013,7(2).
[28]胡义扬,刘平,刘成,等.丹参提取物对CCL_4和DMN诱导的大鼠肝纤维化的影响[J].1999,(10).
[29]Binita Shah,Gaurang Shah.Antifibrotic effect of heparin on liver fibrosis model in rats[J].2012,(6).
[30]Friedman SL.Mechanisms of hepatic fibrogenesis.[J].2008,134(6).
[31]DelBuono,M.,Caporali,C.,DeMaria,N.,etc.Enoxaparin prevents portal vein thrombosis and liver decompensation in patients with advanced cirrhosis[J].2012,143(5).
[32]Hull, Russell,Coffin, Carla S.,Buresi, Michelle.Venous thromboembolism in cirrhosis: A review of the literature[J].2012,26(12).
[33]E. Moreno,J.C. Meneu,J. Calvo,etc.Modulation of Hepatocyte Growth Factor Plasma Levels in Relation to the Dose of Exogenous Heparin Administered: An Experimental Study in Rats[J].2005,37(9).